Search - tctmd.com

Displaying 421 - 440 of 745

Sort: Relevancy | Date

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Todd Neale

September 18, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Marcus A. Banks

July 31, 2019

News Daily News

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

Todd Neale

July 29, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

Advertisement

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

Statins Started in Kids With FH Provide Benefits in Adulthood

Recurrent Events Common Among Young Patients With CAD

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content